未知股票 CODX 深 沪
已收盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 209.50万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 4.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Maxim Group Downgrades Co-Diagnostics to Hold
Maxim Group analyst Jason McCarthy downgrades Co-Diagnostics (NASDAQ:CODX) from Buy to Hold.
01-24 02:27
Co-Diagnostics To Be Delisted From Nasdaq Effective Jan 14, 2026, After Failing Minimum $1.00 Bid Price Rule; Plans Hearing While Trading Moves To OTC Pink
On January 7, 2026, Co-Diagnostics, Inc. (the "Company") received written notice (the "Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") informing the
01-14 01:27
Co-Diagnostics To Implement 1-For-30 Reverse Stock Split, Effective January 2, 2026
Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed a
2025-12-30 22:02
Co-Diagnostics Announces Reverse Stock Split
SALT LAKE CITY, Dec. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the develop...
2025-12-30 22:00
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
The Australian patent represents the first patent granted for the Company's new point-of-care testing platform SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: COD...
2025-12-29 22:00
Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the develop...
2025-12-17 22:00
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. ...
2025-12-09 01:36
Coterra, Ovintiv, Nektar, Co-Diagnostics, Fluence: Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($CTRA) ), ( ($OVV) ), ( ($NKTR) ),...
2025-11-29 17:01
HC Wainwright & Co. Reiterates Neutral on Co-Diagnosticsto Neutral
HC Wainwright & Co. analyst Yi Chen reiterates Co-Diagnostics (NASDAQ:CODX) from Neutral to Neutral.
2025-11-24 20:31
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
